Is Alkermes (ALKS) overvalued or fairly valued?

MarketChacha shows Alkermes's valuation in context — a trailing P/E of about 71.3, a forward P/E of about 32.2, a price-to-book of about 5.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Alkermes's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.41×) from reported figures — education, not a rating.

What is Alkermes's revenue?

Alkermes reported revenue of $1.5B for FY2025, with net profit of $241.7M, per official filings.

What is the share price of Alkermes (ALKS)?

Alkermes last traded at $52.79 (-0.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Alkermes

ALKS · NYSE · Healthcare · United States

$52.79-0.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:31 PM

Snapshot

TickerALKS

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees2,050

HeadquartersDublin, Ireland

Market cap$8.8B

P/E (TTM)71.3

P/B5.0

Volume628.29K

Websitewww.alkermes.com

Filings tracked7

About Alkermes

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.4%
Institutions98.6%
Public & other0.0%

552 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.16.99%
Baker Bros. Advisors, LP6.01%
Vanguard Portfolio Management LLC5.71%
State Street Corporation5.68%
Vanguard Capital Management LLC4.46%
Renaissance Technologies, LLC3.70%
American Century Companies Inc3.64%
Price (T.Rowe) Associates Inc2.80%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 5.0 points over the period — profitability is trending down.

Cash conversion1.41×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend21.4% → 16.4%

Margin has compressed by about 5.0 points over the period — profitability is trending down.

Growth qualityrev -6% · PAT -18%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $472.1M · EPS 0.31

Est. earnings growth -52.1%

Next fiscal year

Rev $1.9B · EPS 1.64

Est. earnings growth +32.8%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$25.1752-wk range$55.67

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$8.8B

Day change

-0.1%

P/E (TTM)

71.3

Fwd P/E

32.2

P/B

5.0

Beta

0.29

Revenue (FY2025)

$1.5B

Net margin

16.4%

ROE

13.3%

Revenue CAGR (2y)

-5.8%

Profit CAGR (2y)

-17.6%

EPS (FY2025)

1.43

Net profit (FY2025)

$241.7M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about ALKS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.5B	$241.7M	1.43	16.4%	13.3%
FY2024	$1.6B	$367.1M	2.17	23.6%	25.1%
FY2023	$1.7B	$355.8M	2.10	21.4%	29.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$392.9M	$-66.5M	-0.40	-16.9%
2025Q3	$394.2M	$82.8M	0.49	21.0%
2025Q2	$390.7M	$87.1M	0.52	22.3%
2025Q1	$306.5M	$22.5M	0.13	7.3%
2024Q3	$378.1M	$92.4M	0.55	24.4%
2024Q2	$399.1M	$91.4M	0.53	22.9%
2024Q1	$350.4M	$36.8M	0.21	10.5%
2023Q3	$380.9M	$47.8M	0.28	12.5%
2023Q2	$617.4M	$237.1M	1.38	38.4%
2023Q1	$287.6M	$-41.8M	-0.25	-14.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Termination of agreement
SEC7/8/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC6/15/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/20/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC5/12/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K/A — Exhibits
SEC5/1/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.